Source comparison
Dual-Pathway GH Release: GHRH vs Ghrelin Receptor Activation
Tesamorelin functions as a GHRH analogue with a trans-3-hexenoic acid modification that extends its half-life to approximately 26–38 minutes. Long enough to sustain receptor occupancy through an entire secretory pulse. When it binds GHRH receptors on pituitary
This comparison does not assign a generated winner or score.
- Tesamorelin functions as a GHRH analogue with a trans-3-hexenoic acid modification that extends its half-life to approximately 26–38 minutes. Long enough to sustain receptor occupancy through an entire secretory pulse. When it binds GHRH receptors on pituitary somatotrophs, it activates adenylyl cyclase, raises intracellular cAMP, and triggers protein kinase A pathways that mobilise pre-synthesised GH from storage granules. Peak plasma GH occurs 60–90 minutes post-administration in rodent models, with levels returning to baseline by 180 minutes.
- Ipamorelin works through an entirely different mechanism. It's a pentapeptide ghrelin mimetic that binds GHS-R1a receptors. The same receptors activated by endogenous ghrelin. Instead of cAMP signalling, Ipamorelin triggers phospholipase C activation, IP3 production, and calcium release from intracellular stores. This calcium surge drives vesicle fusion and GH secretion within 15–30 minutes. Unlike GHRP-6 or GHRP-2, Ipamorelin shows minimal cross-reactivity with cortisol or prolactin pathways, making it exceptionally selective for GH release.
- When both peptides are administered together, the GHRH pathway (Tesamorelin) primes somatotrophs by increasing GH synthesis and granule availability, while the ghrelin pathway (Ipamorelin) provides the calcium-dependent secretory trigger. The result is a GH pulse with 2.5–3.2× higher amplitude than either agent alone, sustained over 4–6 hours rather than the 90-minute window typical of single-agent protocols. Research teams at Real Peptides consistently report this synergy as the primary reason for selecting the blend over monotherapy models.